Anti‐TRK targeted therapies offer opportunities to treat patients with advanced NTRK1/2/3‐rearranged cancers. Beyond NTRK‐rearranged secretory breast carcinomas, little is known about NTRK rearrangements and the expression of TRK proteins in non‐secretory breast carcinomas. We search for TRK proteins expressions using pan‐TRK immunohistochemistry and NTRK1, NTRK2 and NTRK3 rearrangements using fluorescent in situ hybridization (FISH) tests in a set of tissue microarray included breast carcinomas. Only 1/339 invasive breast carcinomas, the only example of secretory subtype, was positive using pan‐TRK immunohistochemistry and harboured a NTRK‐rearrangement (NTRK1 positive FISH test). According to our results, druggable NTRK rearrangements and related‐TRK proteins expression are not encountered in non‐secretory breast carcinomas.

No abstract

No abstract

No abstract

No abstract